Progress in the development of protein biomarkers of oesophageal and gastric cancers

Proteomics - Clinical Applications

Volumn 10, Issue 4, 2016, Pages 532-545

  Coghlin, Caroline ^a   Murray, Graeme I ^b  

^a CRAIGAVON AREA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Biomarker; Diagnosis; Gastric cancer; Immunohistochemistry; Oesophageal cancer predictive; Prognosis

Indexed keywords

TUMOR MARKER; AFM PROTEIN, HUMAN; APOLIPOPROTEIN; CARRIER PROTEIN; GLYCOPROTEIN; SERUM ALBUMIN; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HUMAN; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; EARLY DIAGNOSIS; ESOPHAGEAL NEOPLASMS; GAMMA RADIATION; GENE EXPRESSION; GENETICS; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

APOLIPOPROTEINS; BIOMARKERS, TUMOR; CARRIER PROTEINS; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ESOPHAGEAL NEOPLASMS; GAMMA RAYS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; PROGNOSIS; SERUM ALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS;

EID: 84962720766     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500079     Document Type: Review

References (76)

1. Uppal, D. S., Powell, S. M., Genetics/genomics/proteomics of gastric adenocarcinoma. Gastroenterol. Clin. North Am. 2013, 42, 241-260.
2. Coghlin, C., Murray, G. I., Biomarkers of colorectal cancer: recent advances and future challenges. Proteomics Clin. Appl. 2015, 9, 64-71.
3. Coghlin, C., Murray, G. I., Current and emerging concepts in tumour metastasis. J. Pathol. 2010, 222, 1-15.
4. Coghlin, C., Murray, G. I., The role of gene regulatory networks in promoting cancer progression and metastasis. Future Oncol. 2014, 10, 735-748.
5. Brown, G. T., Murray, G. I., Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 2015, 237, 273-281.
6. Uemura, N., Kondo, T., Current advances in esophageal cancer proteomics. Biochim. Biophys. Acta 2015, 1854, 687-695.
7. Bansal, A., Fitzgerald, R. C., Biomarkers in Barrett's esophagus: role in diagnosis, risk stratification, and prediction of response to therapy. Gastroenterol. Clin. North Am. 2015, 44, 373-390.
8. Ramzan, Z., Nassri, A. B., Huerta, S., The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression. Expert. Rev. Mol. Diagn. 2014, 14, 575-591.
9. Zaidi, A. H., Gopalakrishnan, V., Kasi, P. M., Zeng, X. et al., Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer 2014, 120, 3902-3913.
10. Shah, A. K., Chen, D., Le Cao, K., Choi, E. et al., Discovery and validation of novel serum glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma. Cancer Res. 2014, 74, 2492.
11. Qi, Y. J., Chao, W. X., Chiu, J. F., An overview of esophageal squamous cell carcinoma proteomics. J. Proteomics 2012, 75, 3129-3137.
12. Fu, L., Qin, Y. R., Xie, D., Chow, H. Y. et al., Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 2007, 110, 2672-2681.
13. Fan, N. J., Gao, C. F., Wang, C. S., Zhao, G. et al., Identification of the up-regulation of TP-alpha, collagen alpha-1(VI) chain, and S100A9 in esophageal squamous cell carcinoma by a proteomic method. J. Proteomics 2012, 75, 3977-3986.
14. Fan, N. J., Gao, C. F., Zhao, G., Wang, X. L., Qiao, L., Serum peptidome patterns for early screening of esophageal squamous cell carcinoma. Biotechnol. Appl. Biochem. 2012, 59, 276-282.
15. Fan, N. J., Gao, C. F., Wang, X. L., Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study. OMICS 2013, 17, 215-223.
16. McCormick Matthews, L. H., Noble, F., Tod, J., Jaynes, E. et al., Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br. J. Cancer 2015, 113, 107-118.
17. Pawar, H., Kashyap, M. K., Sahasrabuddhe, N. A., Renuse, S. et al., Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer. Biol. Ther. 2011, 12, 510-522.
18. Kelly, P., Paulin, F., Lamont, D., Baker, L. et al., Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br. J. Cancer 2012, 106, 955-961.
19. Elsner, M., Rauser, S., Maier, S., Schone, C. et al., MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J. Proteomics 2012, 75, 4693-4704.
20. Uemura, N., Nakanishi, Y., Kato, H., Saito, S. et al., Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int. J. Cancer 2009, 124, 2106-2115.
21. Herrmann, K., Walch, A., Balluff, B., Tanzer, M. et al., Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nat. Clin. Pract. Gastroenterol. Hepatol. 2009, 6, 170-183.
22. Aichler, M., Elsner, M., Ludyga, N., Feuchtinger, A. et al., Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J. Pathol. 2013, 230, 410-419.
23. Langer, R., Ott, K., Specht, K., Becker, K. et al., Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin. Cancer Res. 2008, 14, 8279-8287.
24. Syed, N., Barbhuiya, M. A., Pinto, S. M., Nirujogi, R. S. et al., Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. Proteomics 2015, 15, 374-382.
25. Maher, S. G., McDowell, D. T., Collins, B. C., Muldoon, C. et al., Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann. Surg. 2011, 254, 809-816.
26. Roesch-Ely, M., Leipold, A., Nees, M., Holzinger, D. et al., Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J. Pathol. 2010, 221, 462-470.
27. Stingl, C., van Vilsteren, F. G., Guzel, C., Ten Kate, F. J. et al., Reproducibility of protein identification of selected cell types in Barrett's esophagus analyzed by combining laser-capture microdissection and mass spectrometry. J. Proteome Res. 2011, 10, 288-298.
28. Jemal, A., Bray, F., Center, M. M., Ferlay, J. et al., Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
29. Howlader, N., Ries, L. A., Mariotto, A. B., Reichman, M. E. et al., Improved estimates of cancer-specific survival rates from population-based data. J. Natl. Cancer Inst. 2010, 102, 1584-1598.
30. Tashiro, A., Sano, M., Kinameri, K., Fujita, K., Takeuchi, Y., Comparing mass screening techniques for gastric cancer in Japan. World J. Gastroenterol. 2006, 12, 4873-4874.
31. Humphries, J. M., Penno, M. A., Weiland, F., Klingler-Hoffmann, M. et al., Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim. Biophys. Acta 2014, 1844, 1051-1058.
32. Loei, H., Tan, H. T., Lim, T. K., Lim, K. H. et al., Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J. Proteome Res. 2012, 11, 1759-1772.
33. Penno, M. A., Klingler-Hoffmann, M., Brazzatti, J. A., Boussioutas, A. et al., 2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. J. Proteomics 2012, 77, 40-58.
34. Coghlin, C., Murray, G. I., Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics 2013, 13, 2227-2228.
35. Ucar, E., Semerci, E., Ustun, H., Yetim, T. et al., Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv. Ther. 2008, 25, 1075-1084.
36. Liu, X., Cai, H., Wang, Y., Prognostic significance of tumor markers in T4a gastric cancer. World J. Surg. Oncol. 2012, 10, 68.
37. Liu, W., Liu, B., Cai, Q., Li, J. et al., Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin. Chim. Acta 2012, 413, 1098-1106.
38. Mohri, Y., Mohri, T., Wei, W., Qi, Y. J. et al., Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br. J. Cancer 2009, 101, 295-302.
39. Xia, H. H., Yang, Y., Chu, K. M., Gu, Q. et al., Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 2009, 115, 5441-5449.
40. Gomes, C., Almeida, A., Ferreira, J. A., Silva, L. et al., Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J. Proteome Res. 2013, 12, 1454-1466.
41. Chong, P. K., Lee, H., Loh, M. C., Choong, L. Y. et al., Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010, 10, 3210-3221.
42. Ahn, H. S., Shin, Y. S., Park, P. J., Kang, K. N. et al., Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br. J. Cancer 2012, 106, 733-739.
43. Zhu, C., Ren, C., Han, J., Ding, Y. et al., A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br. J. Cancer 2014, 110, 2291-2299.
44. Liu, W., Yang, Q., Liu, B., Zhu, Z., Serum proteomics for gastric cancer. Clin. Chim. Acta 2014, 431, 179-184.
45. Lin, L. L., Huang, H. C., Juan, H. F., Discovery of biomarkers for gastric cancer: a proteomics approach. J. Proteomics 2012, 75, 3081-3097.
46. Wu, J. Y., Cheng, C. C., Wang, J. Y., Wu, D. C. et al., Discovery of tumor markers for gastric cancer by proteomics. PLoS One 2014, 9, e84158.
47. Kon, O. L., Yip, T. T., Ho, M. F., Chan, W. H. et al., The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med. Genomics 2008, 1, 54.
48. Farina, A., Proximal fluid proteomics for the discovery of digestive cancer biomarkers. Biochim. Biophys. Acta 2014, 1844, 988-1002.
49. Wu, W., Juan, W. C., Liang, C. R., Yeoh, K. G. et al., S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin. Appl. 2012, 6, 152-162.
50. Frantzi, M., Latosinska, A., Fluhe, L., Hupe, M. C. et al., Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat. Rev. Urol. 2015, 12, 317-330.
51. Singhal, R., Carrigan, J. B., Wei, W., Taniere, P. et al., MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers. J. Proteomics 2013, 80, 207-215.
52. Chen, J. L., Fan, J., Lu, X. J., CE-MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. Electrophoresis 2014, 35, 1032-1039.
53. Husi, H., Stephens, N., Cronshaw, A., MacDonald, A. et al., Proteomic analysis of urinary upper gastrointestinal cancer markers. Proteomics Clin. Appl. 2011, 5, 289-299.
54. Chen, C. N., Lin, J. J., Chen, J. J., Lee, P. H. et al., Gene expression profile predicts patient survival of gastric cancer after surgical resection. J. Clin. Oncol. 2005, 23, 7286-7295.
55. Xu, Z. Y., Chen, J. S., Shu, Y. Q., Gene expression profile towards the prediction of patient survival of gastric cancer. Biomed. Pharmacother. 2010, 64, 133-139.
56. Balluff, B., Rauser, S., Meding, S., Elsner, M. et al., MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am. J. Pathol. 2011, 179, 2720-2729.
57. Tseng, C. W., Yang, J. C., Chen, C. N., Huang, H. C. et al., Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics 2011, 11, 2423-2439.
58. O'Dwyer, D., Ralton, L. D., O'Shea, A., Murray, G. I., The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011, 6, e27718.
59. Wang, D., Ye, F., Sun, Y., Li, W. et al., Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am. J. Pathol. 2011, 179, 1657-1666.
60. Puig-Costa, M., Codina-Cazador, A., Cortes-Pastoret, E., Oliveras-Ferraros, C. et al., Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget 2014, 5, 1942-1954.
61. Hou, Q., Tan, H. T., Lim, K. H., Lim, T. K. et al., Identification and functional validation of caldesmon as a potential gastric cancer metastasis-associated protein. J. Proteome Res. 2013, 12, 980-990.
62. Yang, W., Raufi, A., Klempner, S. J., Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim. Biophys. Acta 2014, 1846, 232-237.
63. Lin, F., Tan, H. J., Guan, J. S., Lim, Y. P., Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery. Expert. Rev. Proteomics 2014, 11, 515-530.
64. Qian, J., Li, F., Yu, J., Yang, Z., Chen, J., Mining predictive biomarker for neoadjuvant chemotherapy in gastric cancer by proteomics. Hepatogastroenterology 2011, 58, 1828-1833.
65. Yu, Z., Yu, J. K., Fang, X. F., Yuan, Y., Shen, H., Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform. Hepatogastroenterology 2013, 60, 1800-1804.
66. Murray, G. I., An overview of laser microdissection technologies. Acta Histochem. 2007, 109, 171-176.
67. Colarossi, L., Memeo, L., Colarossi, C., Aiello, E. et al., Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics Clin. Appl. 2014, 8, 924-931.
68. Aquino, P. F., Fischer, J. S., Neves-Ferreira, A. G., Perales, J. et al., Are gastric cancer resection margin proteomic profiles more similar to those from controls or tumors? J. Proteome Res. 2012, 11, 5836-5842.
69. Aquino, P. F., Lima, D. B., de Saldanha da Gama Fischer, J., Melani, R. D. et al., Exploring the proteomic landscape of a gastric cancer biopsy with the shotgun imaging analyzer. J. Proteome Res. 2014, 13, 314-320.
70. Sousa, J. F., Ham, A. J., Whitwell, C., Nam, K. T. et al., Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am. J. Pathol. 2012, 181, 1560-1572.
71. Lian, G., Wei, C., Wang, D., Cui, M. et al., Protein profiling of Helicobacter pylori-associated gastric cancer. Am. J. Pathol. 2014, 184, 1343-1354.
72. Cai, Z., Zhao, J. S., Li, J. J., Peng, D. N. et al., A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol. Cell. Proteomics 2010, 9, 2617-2628.
73. Lee, J., Kim, S., Kim, P., Liu, X. et al., A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One 2013, 8, e54644.
74. Bai Z, Ye Y, Liang B, Xu F, et al., Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. Int. J. Oncol. 2011, 38, 375-383.
75. Marimuthu, A., Subbannayya, Y., Sahasrabuddhe, N. A., Balakrishnan, L. et al., SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin. Appl. 2013, 7, 355-366.
76. Ralton, L. D., Murray, G. I., The use of formalin fixed wax embedded tissue for proteomic analysis. J. Clin. Pathol. 2011, 64, 297-302.